keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer recurrence

keyword
https://www.readbyqxmd.com/read/28924059/pygopus2-expression-in-prostatic-adenocarcinoma-is-a-potential-risk-stratification-marker-for-psa-progression-following-radical-prostatectomy
#1
Kenneth R Kao, Paul Popadiuk, John Thoms, Satoko Aoki, Shahgul Anwar, Emily Fitzgerald, Phillip Andrews, Kim Voisey, Luis Gai, Satya Challa, Zhijian He, Paola Gonzales-Aguirre, Andrea Simmonds, Catherine Popadiuk
AIMS: Prostate cancer (PrCa) is the most frequently diagnosed non-cutaneous cancer in men. Without clear pathological indicators of disease trajectory at diagnosis, management of PrCa is challenging, given its wide-ranging manifestation from indolent to highly aggressive disease. This study examines the role in PrCa of the Pygopus (PYGO)2 chromatin effector protein as a risk stratification marker in PrCa. METHODS: RNA expression was performed in PrCa cell lines using Northern and RT-PCR analyses...
September 18, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28923561/update-on-the-safety-of-phosphodiesterase-type-5-inhibitors-for-the-treatment-of-erectile-dysfunction
#2
REVIEW
Faysal A Yafi, Ira D Sharlip, Edgardo F Becher
INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5Is) have demonstrated efficacy in the treatment of erectile dysfunction (ED). Although historically found to have limited drug-related adverse events, emerging data have suggested that PDE5Is might be associated with melanoma or recurrence of prostate cancer after radical prostatectomy. AIM: To summarize the literature on the safety of PDE5Is. METHODS: A literature review was performed through PubMed from 1990 through 2016 regarding ED...
September 8, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28923030/the-eef1a2-gene-expression-as-risk-predictor-in-localized-prostate-cancer
#3
Thomas Stefan Worst, Frank Waldbillig, Abdallah Abdelhadi, Cleo-Aron Weis, Maria Gottschalt, Annette Steidler, Jost von Hardenberg, Maurice Stephan Michel, Philipp Erben
BACKGROUND: Besides clinical stage and Gleason score, risk-stratification of prostate cancer in the pretherapeutic setting mainly relies on the serum PSA level. Yet, this is associated with many uncertainties. With regard to therapy decision-making, additional markers are needed to allow an exact risk prediction. Eukaryotic translation elongation factor 1 alpha 2 (EEF1A2) was previously suggested as driver of tumor progression and potential biomarker. In the present study its functional and prognostic relevance in prostate cancer was investigated...
September 18, 2017: BMC Urology
https://www.readbyqxmd.com/read/28922958/post-prostatectomy-radiation-therapy-for-locally-recurrent-prostate-cancer
#4
Sudhir Isharwal, Andrew J Stephenson
Approximately 15-30% of men with localized prostate cancer will experience biochemical recurrence (BCR) after radical prostatectomy. Postoperative radiation therapy is used in men with adverse pathological features to reduce the risk of BCR or with curative intent in men with known BCR. In this study, we review the evidence for the adjuvant and salvage radiation therapy after radical prostatectomy. Areas covered: A literature review of the Medline and Embase databases was performed. The search strategy included the following terms: prostate cancer, adjuvant radiotherapy, salvage radiotherapy, radical prostatectomy, biochemical recurrence, and prostate cancer recurrence...
September 18, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28919101/3-4%C3%A2-6-implications-of-the-stratification-of-localised-gleason-7-prostate-cancer-by-number-and-percentage-of-positive-biopsy-cores-in-selecting-patients-for-active-surveillance
#5
J L Ruiz-Cerdá, L Lorenzo Soriano, D Ramos-Soler, L Marzullo-Zucchet, A Loras Monfort, F Boronat Tormo
OBJECTIVE: To determine whether the number and percentage of positive biopsy cores identify a Gleason 3+4 prostate cancer (PC) subgroup of similar biologic behaviour to Gleason 3+3. MATERIAL AND METHOD: An observational post-radical prostatectomy study was conducted of a cohort of 799 patients with localised low-risk (n=582, Gleason 6, PSA <10ng/ml and cT1c-2a) and favourable intermediate PC (n=217, Gleason 3+4, PSA ≤10 ng/ml and pT2abc). The Gleason 3+4 tumours were stratified by number (≤3 vs...
September 14, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28918830/metformin-has-positive-therapeutic-effects-in-colon-cancer-and-lung-cancer
#6
DeAnna Henderson, Danielle Frieson, Jeffrey Zuber, Solomon S Solomon
BACKGROUND: Metformin (MF), a diabetic drug, has antineoplastic activity as adjuvant therapy for breast cancer and prostate cancer. MF is thought to work via inhibition of mammalian target of rapamycin and activation of p53 and liver kinase B1 via adenosine 5'-monophosphate-activated protein kinase. We investigated survival, recurrences and metastasis in patients with type 2 diabetes mellitus (DM2) along with colorectal cancer (CC) or lung cancer (LC) taking MF using the electronic medical record in Memphis Veterans Affairs Medical Center (colon, n = 202; lung, n = 180)...
September 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28916284/stereotactic-body-radiotherapy-versus-low-dose-rate-brachytherapy-for-localised-prostate-cancer-a-cost-utility-analysis
#7
J Helou, S Torres, H B Musunuru, J Raphael, P Cheung, D Vesprini, H T Chung, L D'Alimonte, M Krahn, G Morton, A Loblaw
AIMS: To conduct a cost-utility analysis comparing stereotactic body radiotherapy (SBRT) with low dose rate brachytherapy (LDR-BT) for localised prostate cancer (PCa). MATERIALS AND METHODS: A decision-analytic Markov model was developed from the healthcare payer perspective to simulate the history of a 66-year-old man with low-risk PCa. The model followed patients yearly over their remaining lifetimes. Health states included 'recurrence-free', 'biochemical recurrence' (BR), 'metastatic' and 'death'...
September 12, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28916273/identification-of-recurrence-sites-following-post-prostatectomy-treatment-for-prostate-cancer-using-11-c-choline-positron-emission-tomography-and-multiparametric-pelvic-mri
#8
Avinash Nehra, William P Parker, Rimki Haloi, Sean S Park, Lance A Mynderse, Val J Lowe, Brian J Davis, J Fernando Quevedo, Geoffrey B Johnson, Eugene D Kwon, R Jeffrey Karnes
PURPOSE: To describe anatomic sites of recurrence among prostate cancer patients with biochemical recurrence following radical prostatectomy (RP) and postoperative radiotherapy (RT) and/or androgen deprivation therapy (ADT) using (11)C-Choline PET/CT and multiparametric-MRI. MATERIALS AND METHODS: RP patients evaluated with (11)C-Choline PET/CT and multiparametric-MRI following RT and/or ADT were evaluated for patterns of recurrence and clinicopathologic features...
September 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28916253/the-place-of-transanal-endoscopic-surgery-in-the-treatment-of-recto-urethral-fistula
#9
X Serra-Aracil, M Labro-Ciurans, L Mora-Lopez, J Muñoz-Rodriguez, R Martos-Calvo, J Prats-López, S Navarro-Soto
OBJECTIVES: To assess the role of TEO/TEM in recto-urethral fistulas (RUF). RUF may appear after radical prostatectomy. Their treatment represents a challenge; many therapies have been proposed, from conservative to aggressive surgical approaches. Transanal endoscopic surgery (TEO/TEM) is a minimally invasive technique to access the site of the RUF to perform repair. METHODS: Observational study with prospective data collection, conducted between September 2006 and December 2015...
September 12, 2017: Urology
https://www.readbyqxmd.com/read/28915709/the-prognostic-value-of-long-noncoding-rnas-in-prostate-cancer-a-systematic-review-and-meta-analysis
#10
REVIEW
Weijie Ma, Xi Chen, Lu Ding, Jianhong Ma, Wei Jing, Tian Lan, Haseeb Sattar, Yongchang Wei, Fuling Zhou, Yufeng Yuan
The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, we conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into our analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS) (HR = 1...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28905446/impact-of-five-tiered-gleason-grade-groups-on-prognostic-prediction-in-clinical-stage-t3-prostate-cancer-undergoing-high-dose-rate-brachytherapy
#11
Hideyasu Tsumura, Hiromichi Ishiyama, Ken-Ichi Tabata, Hiroki Katsumata, Momoko Kobayashi, Masaomi Ikeda, Shinji Kurosaka, Tetsuo Fujita, Masashi Kitano, Takefumi Satoh, Nobuyuki Yanagisawa, Kazushige Hayakawa, Masatsugu Iwamura
BACKGROUND: We evaluated a five-tiered Gleason grade groups arising from the 2014 International Society of Urological Pathology consensus conference on prognostic prediction in clinical stage T3a (extracapsular invasion) and T3b (seminal vesicle involvement) prostate cancer undergoing high-dose-rate brachytherapy (HDR-BT). METHODS: From November 2003 to December 2012, 283 patients with stage T3 prostate cancer received HDR-BT and external beam radiation therapy (EBRT) with long-term androgen deprivation therapy (ADT)...
September 14, 2017: Prostate
https://www.readbyqxmd.com/read/28905289/lymph-node-positive-prostate-cancer-after-robotic-prostatectomy-and-extended-pelvic-lymphadenectomy
#12
Avinash Chenam, Jaspreet S Parihar, Nora Ruel, Sumanta Pal, Yvonne Avila, Jonathan Yamzon, Clayton Lau, Bertram Yuh
Optimal management of node-positive prostate cancer patients after prostatectomy remains a challenge. We evaluated clinically localized patients who demonstrated node positivity and identified predictors for secondary treatment. From 2010 to 2015, clinically localized prostate cancer patients who underwent robot prostatectomy with extended lymphadenectomy and node-positive disease on pathologic analysis were identified. Clinical N1, M1 or salvage cases were excluded. Patients were stratified based on secondary treatments...
September 13, 2017: Journal of Robotic Surgery
https://www.readbyqxmd.com/read/28904361/intrafascial-versus-interfascial-nerve-sparing-in-radical-prostatectomy-for-localized-prostate-cancer-a-systematic-review-and-meta-analysis
#13
Hong Weng, Xian-Tao Zeng, Sheng Li, Xiang-Yu Meng, Ming-Jun Shi, Da-Lin He, Xing-Huan Wang
The present study aimed to systematically evaluate the effectiveness and safety of the intrafascial and interfascial nerve sparing (ITR-NS and ITE-NS) radical prostatectomy. PubMed, Embase, and Cochrane Library databases were searched for eligible studies. Meta-analysis with random-effects model was performed. Six comparative trials were selected and embraced in this research, including one randomized controlled trial, three prospective comparative trials, and two retrospective comparative trials. With regard to perioperative parameters, no significant association of operative time, blood loss, transfusion rates, duration of catheterization, and hospital stay existed between ITR-NS and ITE-NS...
September 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28900854/relationships-between-serum-psa-levels-gleason-scores-and-results-of-68ga-psmapet-ct-in-patients-with-recurrent-prostate-cancer
#14
Yasemin Sanli, Serkan Kuyumcu, Oner Sanli, Fikret Buyukkaya, Ayça İribaş, Goksel Alcin, Emin Darendeliler, Yasemin Ozluk, Sevda Ozel Yildiz, Cüneyt Turkmen
AIM: To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga(68)-PSMA PET/CT in patients with recurrent PCa. METHODS: A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented...
September 12, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28895658/laparoscopic-and-robotic-assisted-versus-open-radical-prostatectomy-for-the-treatment-of-localised-prostate-cancer
#15
REVIEW
Dragan Ilic, Sue M Evans, Christie Ann Allan, Jae Hung Jung, Declan Murphy, Mark Frydenberg
BACKGROUND: Prostate cancer is commonly diagnosed in men worldwide. Surgery, in the form of radical prostatectomy, is one of the main forms of treatment for men with localised prostate cancer. Prostatectomy has traditionally been performed as open surgery, typically via a retropubic approach. The advent of laparoscopic approaches, including robotic-assisted, provides a minimally invasive alternative to open radical prostatectomy (ORP). OBJECTIVES: To assess the effects of laparoscopic radical prostatectomy or robotic-assisted radical prostatectomy compared to open radical prostatectomy in men with localised prostate cancer...
September 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28895177/a-novel-use-for-olaparib-for-treatment-of-metastatic-castration-recurrent-prostate-cancer
#16
Grace A Martin, Adrienne H Chen, Kinjal Parikh
Although mortality from prostate cancer has declined over the past 20 years as a result of early detection and treatment, the 5-year survival rate for men with prostate cancer who develop metastatic disease is only 29%. Current treatment options for metastatic castration-recurrent prostate cancer (mCRPC) are associated with toxicity and a limited durable response; therefore, additional lines of efficacious and minimally toxic therapy are needed. Olaparib, a poly(adenosine 5'-diphosphate) ribose polymerase (PARP) inhibitor, received United States Food and Drug Administration breakthrough therapy designation in January 2016 for the treatment of patients with BRCA1/2 or ATM gene-mutated mCRPC based on results of a compelling phase II trial of olaparib in patients with advanced castration resistant prostate cancer (TOPARP-A)...
September 12, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28894899/clinical-impact-of-psma-based-18-f-dcfbc-pet-ct-imaging-in-patients-with-biochemically-recurrent-prostate-cancer-after-primary-local-therapy
#17
Esther Mena, Maria L Lindenberg, Joanna H Shih, Stephen Adler, Stephanie Harmon, Ethan Bergvall, Deborah Citrin, William Dahut, Anita T Ton, Yolanda McKinney, Juanita Weaver, Philip Eclarinal, Alicia Forest, George Afari, Sibaprasad Bhattacharyya, Ronnie C Mease, Maria J Merino, Peter Pinto, Bradford J Wood, Paula Jacobs, Martin G Pomper, Peter L Choyke, Baris Turkbey
PURPOSE: The purpose of our study was to assess (18)F-DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment. METHODS: This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging...
September 11, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28890840/err%C3%AE-regulates-the-growth-of-triple-negative-breast-cancer-cells-via-s6k1-dependent-mechanism
#18
Adi Y Berman, Subrata Manna, Naomi S Schwartz, Yardena E Katz, Yang Sun, Catherine A Behrmann, Jane J Yu, David R Plas, Anya Alayev, Marina K Holz
Estrogen-related receptor alpha (ERRα) is an orphan nuclear factor that is a master regulator of cellular energy metabolism. ERRα is overexpressed in a variety of tumors, including ovarian, prostate, colorectal, cervical and breast, and is associated with a more aggressive tumor and a worse outcome. In breast cancer, specifically, high ERRα expression is associated with an increased rate of recurrence and a poor prognosis. Because of the common functions of ERRα and the mTORC1/S6K1 signaling pathway in regulation of cellular metabolism and breast cancer pathogenesis, we focused on investigating the biochemical relationship between ERRα and S6K1...
2017: Signal Transduction and Targeted Therapy
https://www.readbyqxmd.com/read/28889366/performance-of-68-ga-psma-pet-ct-for-prostate-cancer-management-at-initial-staging-and-time-of-biochemical-recurrence
#19
REVIEW
Jason Bailey, Morand Piert
PURPOSE OF THE REVIEW: Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC ((68)Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. RECENT FINDINGS: (68)Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, (68)Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that (68)Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL)...
September 9, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28887398/-64-cucl2-pet-ct-in-prostate-cancer-relapse
#20
Arnoldo Piccardo, Francesco Paparo, Matteo Puntoni, Sergio Righi, Gianluca Bottoni, Lorenzo Bacigalupo, Silvia Zanardi, Andrea DeCensi, Giulia Ferrarazzo, Monica Gambaro, Filippo Grillo Ruggieri, Fabio Campodonico, Laura Tomasello, Luca Timossi, Simona Sola, Egesta Lopci, Manlio Cabria
To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated...
September 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
33996
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"